DATABASE · 2,000+ PEER-REVIEWED CITATIONS INDEXEDCOMPOUND LIBRARY · 100+ EVIDENCE-GRADED RECORDSGRADE A EVIDENCE · 45 COMPOUNDS WITH MULTIPLE HUMAN RCTSHUMAN EVIDENCE · 97 COMPOUNDS WITH HUMAN STUDY DATAVENDOR DIRECTORY · 11 RESEARCH VENDORS TRACKEDCLINIC DIRECTORY · 10 TELEHEALTH PROVIDERS VETTEDCOA RECORDS · 7 BATCH CERTIFICATES ON FILELIVE DATABASE · UPDATED 2D AGODATABASE · 2,000+ PEER-REVIEWED CITATIONS INDEXEDCOMPOUND LIBRARY · 100+ EVIDENCE-GRADED RECORDSGRADE A EVIDENCE · 45 COMPOUNDS WITH MULTIPLE HUMAN RCTSHUMAN EVIDENCE · 97 COMPOUNDS WITH HUMAN STUDY DATAVENDOR DIRECTORY · 11 RESEARCH VENDORS TRACKEDCLINIC DIRECTORY · 10 TELEHEALTH PROVIDERS VETTEDCOA RECORDS · 7 BATCH CERTIFICATES ON FILELIVE DATABASE · UPDATED 2D AGO
Home/Compounds/Teriparatide
OtherFDA approvedRx required

Teriparatide

Also known as: Forteo · Bonsity
Brands: Forteo · Bonsity

Recombinant 1-34 fragment of human parathyroid hormone; first bone-forming agent approved for osteoporosis.

A
Grade A
Multiple human RCTs
Human studies25
PubMed citations28
Routesubcutaneous
Regulatory (US)FDA approved · Rx
Last verified2 days ago

Mechanism of action

Recombinant human PTH(1-34). Intermittent daily dosing stimulates osteoblast activity and bone formation (unlike continuous PTH, which is catabolic).

Evidence summary

25
Human studies
28
PubMed citations
25
Clinical trials
A
Evidence grade

Evidence summary in progress. See the citations section below for the underlying research papers.

Dosing protocols

Educational information only. Consult a licensed provider before using any peptide.
Administration routes
subcutaneous

Side effects & safety

From the FDA label
Source
arthralgiaastheniaconstipationdiarrheadizzinessdyspepsiaheadacheinjection site paininsomnianausearashurticariavomiting

Terms pulled directly from the referenced source. We don't fabricate frequencies — when a label doesn't publish a percentage, we don't either.

Interactions

No documented drug interactions on file.

Regulatory status

United States
FDA approved

FDA approved for osteoporosis at high fracture risk (Forteo, Bonsity). Carries a previous boxed warning for osteosarcoma that was removed in 2020.

Compounding
Not permitted

Not available via 503A/503B compounding pharmacies.

Regulatory data last verified 4/19/2026

Clinical trials

NCT06558188Combined Anabolic Therapy StudyRecruiting · Phase 4 · Osteoporosis, Postmenopausal · n=50NCT06264609Novel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover - Follow Up StudyEnrolling By Invitation · Phase 4 · Osteoporosis · n=40NCT07497503A Randomised, Double-Blind, Two-Sequence, Single-Dose, Crossover Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity Profile of B-3E07 and Forsteo in Healthy Adult Female ParticipantsNot Yet Recruiting · Phase 1 · Healthy Volunteers · n=48NCT05965167A Phase 1b, Open-label, Partially Randomised Study to Assess Safety and Compare Pharmacokinetics of New Oral hPTH(1-34) Tablet Formulations vs. Oral EBP05 Tablets and Subcutaneous Forteo® Injection in Healthy Male SubjectsCompleted · Phase 1 · Hypoparathyroidism · n=45NCT05866029Efficacy of Sequential Denosumab After Teriparatide for 6 Months Compared With Denosumab Monotherapy in Reducing Risk of Osteoporotic Fractures in Patients With New Fractures: a Multicenter Randomized Controlled Trial (STAND Study)Recruiting · N/A · Osteoporotic Fractures · n=2478NCT01225055Effect of Teriparatide, Vibration and the Combination on Bone Mass and Bone Architecture in Chronic Spinal Cord InjuryCompleted · Phase 2 · Spinal Cord Injury · n=60NCT03232476Effect of Mechanical Loading With PTH on Cortical BoneWithdrawn · Phase 4 · Osteoporosis, PostmenopausalNCT07242612Determination of Selective Bone Turnover Markers and Their Association With Treatment Efficacy in Primary Postmenopausal Osteoporotic Women: A Randomized Control TrialRecruiting · N/A · Osteoporosis · n=40NCT03735537Treatment of Osteogenesis Imperfecta With Parathyroid Hormone and Zoledronic AcidCompleted · Phase 4 · Osteogenesis Imperfecta · n=350NCT03994172Novel Combination Therapy for Osteoporosis in MenActive Not Recruiting · Phase 4 · Male Osteoporosis · n=40NCT04669782Osteocalcin in Bone Metabolism and Aging: Effect of Vitamin K Supplementation on Circulating Levels of Osteocalcin, on Glucose and Energy Metabolism and on Muscle Mass and FunctionTerminated · N/A · Bone Metabolism Disorder · n=99NCT06644040A Randomized, Open-Label, Active-Controlled, 3-Way, Incomplete Block, Crossover, Single Escalating Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of TeriQ Patch in Healthy Adult Female ParticipantsCompleted · Phase 1 · Osteoporosis · n=24

Showing 12 of 25 indexed studies. View all on ClinicalTrials.gov →

Citations

PMID 37522550Salave S, Rana D et al. · Recent Advances in Teriparatide Delivery by-virtue-of Novel Drug Delivery Approaches for the Management of Osteoporosis.Critical reviews in therapeutic drug carrier systems (2026)HumanPMID 40611602Shima K, Shimizu T et al. · Strontium-Loaded Titanium and Systemic Teriparatide Synergistically Enhance Osteogenesis and Osseointegration in an Osteoporotic Rabbit Model.Journal of biomedical materials research. Part A (2025)HumanPMID 21857768Dhillon RS, Schwarz EM · Teriparatide Therapy as an Adjuvant for Tissue Engineering and Integration of Biomaterials.Materials (Basel, Switzerland) (2025)HumanPMID 39657234Kobayakawa T, Nakamura Y · Verifying the effectiveness of romosozumab re-administration on bone mineral density.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research (2025)HumanPMID 41114847Stumpf U, Kurth A · [Osteo-anabolic treatment strategies].Orthopadie (Heidelberg, Germany) (2025)HumanPMID 38107811Arora MK, Kumar L et al. · Combination Therapy of Denosumab and Teriparatide in Osteoporosis.Indian journal of orthopaedics (2024)PMID 39312040Li M, Ge Z et al. · Efficacy and safety of teriparatide vs. bisphosphonates and denosumab vs. bisphosphonates in osteoporosis not previously treated with bisphosphonates: a systematic review and meta-analysis of randomized controlled trials.Archives of osteoporosis (2024)HumanPMID 38976019Anastasilakis AD, Polyzos SA et al. · The comparative effect of teriparatide and denosumab on activins, follistatins, and inhibins in women with postmenopausal osteoporosis.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research (2024)HumanPMID 39640163Nunkoo S, Krissheeven M et al. · Clinical Efficacy and Safety of Teriparatide Versus Alendronate in Postmenopausal Osteoporosis: A Systematic Review of Randomized Controlled Trials.Cureus (2024)PMID 38654732Fassio A, Gatti D et al. · The sequential antifracturative treatment: a meta-analysis of randomized clinical trials.Therapeutic advances in musculoskeletal disease (2024)HumanPMID 38107815Sauhta R, Makkar D et al. · The Sequential Therapy in Osteoporosis.Indian journal of orthopaedics (2024)HumanPMID 39365433Borgström F, Lorentzon M et al. · Cost-effectiveness intervention thresholds for romosozumab and teriparatide in the treatment of osteoporosis in the UK.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2024)HumanPMID 36210087McConnell M, Shieh A · Polypharmacy in Osteoporosis Treatment.Clinics in geriatric medicine (2022)HumanPMID 36111201Krege JH, Gilsenan AW et al. · Teriparatide and Osteosarcoma Risk: History, Science, Elimination of Boxed Warning, and Other Label Updates.JBMR plus (2022)HumanPMID 36382760Bandeira L, Lewiecki EM · Anabolic therapy for osteoporosis: update on efficacy and safety.Archives of endocrinology and metabolism (2022)HumanPMID 33538953Marcucci G, Masi L et al. · Chronic hypoparathyroidism and treatment with teriparatide.Endocrine (2021)HumanPMID 30694878Chen Y, Liu R et al. · Clinical Application of Teriparatide in Fracture Prevention: A Systematic Review.JBJS reviews (2020)HumanPMID 31990595Anastasilakis AD, Polyzos SA et al. · Combination and sequential treatment in women with postmenopausal osteoporosis.Expert opinion on pharmacotherapy (2020)HumanPMID 31509477Cheng C, Wentworth K et al. · New Frontiers in Osteoporosis Therapy.Annual review of medicine (2020)HumanPMID 30856013Merlotti D, Falchetti A et al. · Efficacy and safety of abaloparatide for the treatment of post-menopausal osteoporosis.Expert opinion on pharmacotherapy (2019)Human

Showing 20 of 28 papers. View all on PubMed →